RG7386 / Roche - LARVOL DELTA

Emerging new therapeutic antibody derivatives for cancer treatment (Nature) - "...RG7386/RO6874813, a symmetric tetravalent 2:2 CrossMab BsAb that possesses a high affinity for fibroblast activation protein (FAP) on tumor stromal fibroblasts and low affinity for death receptor 5 (DR5), potently triggered death receptor-mediated apoptosis of tumor cells while sparing normal cells. This anti-FAP×DR5 BsAb demonstrated superior antitumor efficacy against FAP-expressing malignant cells in vitro as well as in patient-derived xenograft mouse models compared to that of conventional DR5 antibodies."

Preclinical • Oncology • Solid Tumor

A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=120; Not yet recruiting; Sponsor: Hoffmann-La Roche

Clinical • New P1 trial • Oncology • Solid Tumor • FDG PET

A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=120; Recruiting; Sponsor: Hoffmann-La Roche; Trial primary completion date: Sep 2017 ➔ Jun 2019

Clinical • Trial primary completion date • Oncology • Solid Tumor • FDG PET

A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=120; Recruiting; Sponsor: Hoffmann-La Roche; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Oncology • Solid Tumor • FDG PET

A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=120; Active, not recruiting; Sponsor: Hoffmann-La Roche; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Oncology • Solid Tumor • FDG PET

A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=120; Completed; Sponsor: Hoffmann-La Roche; Active, not recruiting ➔ Completed; Trial completion date: Aug 2019 ➔ Nov 2017; Trial primary completion date: Jun 2019 ➔ Nov 2017

Clinical • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • FDG PET